The Evolving AML Treatment Landscape: Considerations for Oncology Nursing

These live webinars feature management insights from nursing experts for patients with acute myeloid leukemia (AML), including education on strategies for adverse event management and patient communication.


Introduction: Acute Myeloid Leukemia

Individualizing AML Treatment
--Disease and Patient Characteristics
--Cytogenetic and Molecular Mutations

Treating Patients With Newly Diagnosed AML

Treating Patients With Relapsed/Refractory AML

Adverse Event Monitoring and Management

Supportive Care for Patients With AML


Date / Time
Event Details


Elizabeth Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ayelet Nelson, ANP-BC

Outpatient Leukemia Nurse Practitioner
Division of Hematology/Oncology
Weill Cornell Medicine
New York, New York

Goal Statement
The goal of this continuing education activity is to enhance knowledge and clinical competency among oncology nurses in the nursing care of patients with AML.

Target Audience
The proposed learning activities are intended for oncology nurses, NPs and other health care providers who manage and care for patients with AML. This includes nursing professionals affiliated with community and academic hospitals, oncology practices or healthcare systems.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the phases of AML therapy (including treating leukostasis, and induction/consolidation therapy)
  • Outline individualized management plans for AML based on disease, patient, and agent characteristics.
  • Identify recommendations for cytogenetic and molecular biomarkers that are used to select therapy in AML.
  • Review newer approved and investigational targeted agents used along with chemotherapy for improved outcomes.
  • Identify strategies for addressing quality-of-life concerns, supportive care needs for patients with AML.
    Discuss the management of treatment-related adverse events for patients with AML.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nursing Continuing Education

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Clinical Care Options do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.­­­